Skip to main content

Acumen Pharmaceuticals, Inc. (ABOS)

NASDAQ: ABOS · Delayed Price · USD
16.23 0.05 (0.31%)
Sep 17, 2021 4:00 PM EDT - Market closed
Market Cap627.32M
Revenue (ttm)1.06M
Net Income (ttm)-32.28M
Shares Out38.65M
EPS (ttm)-0.84
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Close16.18
Day's Range15.86 - 17.71
52-Week Range13.95 - 26.98
Price Target25.00 (+54.0%)
Est. Earnings DateNov 16, 2021

About ABOS

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer’s disease, or AD. Based on decades of research and supporting evidence, soluble amyloid-beta oligomers, or AbOs have gained increasing scientific acceptance as a primary toxin involved in the initiation and propagation of AD pathology. We are currently focused on advancing a targeted immunotherapy drug candidate, ACU193, and establishing proof of mechanism in ear...

IPO DateJul 1, 2021
CEODaniel O’Connell
Stock ExchangeNASDAQ
Ticker SymbolABOS
Full Company Profile

Financial Performance

Financial Statements


Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2021 and Business Highlights

CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical stage biopharmaceutical company focused on the development of no...

1 month ago - GlobeNewsWire

5 Stocks With High Insider Cluster Buys During July

According to the Insider Cluster Buys Screen, a Premium feature of Gurus, five stocks with high number of unique insider buys during the past month include German American Bancorp Inc. ( GABC , Financia...

1 month ago - GuruFocus

Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering

CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (“Acumen” or “Acumen Pharmaceuticals”) (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a novel ...

2 months ago - GlobeNewsWire

Acumen Pharmaceuticals IPO Registration Document (S-1)

Acumen Pharmaceuticals, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC